Patient-Reported Communication With Their Health Care Team About New Treatment Options for Chronic Lymphocytic Leukemia
© The Author(s) 2021..
Chronic lymphocytic leukemia (CLL) often requires consideration of multiple treatment options. Shared decision-making (SDM) is important, given the availability of increasingly novel therapies; however, patient-provider treatment conversations vary. We examined relationships between patient-provider discussions of new CLL treatment options and sociodemographic, clinical, and patient-provider communication variables among 187 CLL patients enrolled in Cancer Support Community's Cancer Experience Registry. Factors significantly associated with self-reports of whether patients' providers discussed new CLL treatment options with them were examined using χ2 tests, t tests, and hierarchical logistic regression. Fifty-eight percent of patients reported discussing new treatment options with their doctor. Patients with higher education were 3 times more likely to discuss new treatment options relative to those with lower education (OR = 3.06, P < .05). Patients who experienced a cancer recurrence were 7 times more likely to discuss new treatment options compared to those who had not (OR = 7.01, P < .05). Findings offer insights into the correlates of patient-provider discussions of new CLL treatment options. As novel therapies are incorporated into standards of care, opportunities exist for providers to improve patient care through enhanced SDM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of patient experience - 8(2021) vom: 20., Seite 23743735211034967 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kranzler, Elissa C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic lymphocytic leukemia |
|---|
| Anmerkungen: |
Date Revised 31.08.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/23743735211034967 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330013742 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330013742 | ||
| 003 | DE-627 | ||
| 005 | 20231225210358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/23743735211034967 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1100.xml |
| 035 | |a (DE-627)NLM330013742 | ||
| 035 | |a (NLM)34458567 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kranzler, Elissa C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient-Reported Communication With Their Health Care Team About New Treatment Options for Chronic Lymphocytic Leukemia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.08.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2021. | ||
| 520 | |a Chronic lymphocytic leukemia (CLL) often requires consideration of multiple treatment options. Shared decision-making (SDM) is important, given the availability of increasingly novel therapies; however, patient-provider treatment conversations vary. We examined relationships between patient-provider discussions of new CLL treatment options and sociodemographic, clinical, and patient-provider communication variables among 187 CLL patients enrolled in Cancer Support Community's Cancer Experience Registry. Factors significantly associated with self-reports of whether patients' providers discussed new CLL treatment options with them were examined using χ2 tests, t tests, and hierarchical logistic regression. Fifty-eight percent of patients reported discussing new treatment options with their doctor. Patients with higher education were 3 times more likely to discuss new treatment options relative to those with lower education (OR = 3.06, P < .05). Patients who experienced a cancer recurrence were 7 times more likely to discuss new treatment options compared to those who had not (OR = 7.01, P < .05). Findings offer insights into the correlates of patient-provider discussions of new CLL treatment options. As novel therapies are incorporated into standards of care, opportunities exist for providers to improve patient care through enhanced SDM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic lymphocytic leukemia | |
| 650 | 4 | |a patient education | |
| 650 | 4 | |a patient–provider communication | |
| 650 | 4 | |a shared decision-making | |
| 700 | 1 | |a Olson, Julie S |e verfasserin |4 aut | |
| 700 | 1 | |a Nichols, Helen M |e verfasserin |4 aut | |
| 700 | 1 | |a Yuen, Eva Yn |e verfasserin |4 aut | |
| 700 | 1 | |a McManus, Shauna |e verfasserin |4 aut | |
| 700 | 1 | |a Buzaglo, Joanne S |e verfasserin |4 aut | |
| 700 | 1 | |a Zaleta, Alexandra K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of patient experience |d 2014 |g 8(2021) vom: 20., Seite 23743735211034967 |w (DE-627)NLM27080708X |x 2374-3735 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g day:20 |g pages:23743735211034967 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/23743735211034967 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |b 20 |h 23743735211034967 | ||